SciSparc's SCI-110 Shows Promise in Phase IIb Trial for Tourette Syndrome

SciSparc Ltd. SPRC, a clinical-stage pharmaceutical company, is making waves with the recent update on their Phase IIb trial for SCI-110, a proprietary THC-based medication. This drug is garnering attention due to its potential to treat Tourette Syndrome (TS), a neurological condition characterized by involuntary tics and vocalizations. With a focus on advancing treatment options for TS, SciSparc's trial is a beacon of hope for individuals affected by this disorder.

Collaborative Efforts in TS Research

SCI-110's trial is a product of global efforts, involving prestigious institutions like Yale University, Tel Aviv Sourasky Medical Center, and Hannover Medical School. Governed by the regulatory standards of the Food and Drug Administration, BfArM, and the Israeli Ministry of Health, the trial represents a coordinated initiative to address TS with innovative solutions.

The drug SCI-110, which integrates FDA-approved synthetic THC (Dronabinol) with palmitoylethanolamide, aims to modulate the cannabinoid receptors within the central nervous system. This combination could potentially fill a significant void in the current management of TS.

The Potential of SCI-110

SCI-110, which is designed for oral use, strives for high efficacy with a desire to minimize side effects by reducing dosages. The target demographic for the trial includes adults from 18 to 65 years of age, and the drug's efficacy is measured against a placebo using the Yale Global Tic Severity Scale.

In the earlier Phase IIA trials at Yale University, SCI-110 displayed a noteworthy reduction in tics, averaging at 21%, with some participants experiencing over a 25% decline. This strong performance was complemented by the fact that 12 out of 16 individuals chose to extend their participation to a 24-week period, indicating a favorable reception to the drug's tolerability.

Apart from SCI-110, SciSparc is also spearheading cannabinoid pharmaceutical programs such as SCI-160 for pain management and SCI-210 addressing ASD and status epilepticus. These efforts emphasize SciSparc's dedication to the field of cannabinoid-based treatments.

SPRC has indicated that the outcomes of the Phase IIb trial mark a potential groundbreaking step in TS therapy, suggesting a promise of improved efficiency and safety.

Cannabinoid Pharmaceuticals: A Forward Movement

SciSparc's commitment to cannabinoid pharmaceuticals doesn't stop at SCI-110. Their diverse portfolio includes research into Alzheimer's treatment, pain management, ASD, and status epilepticus, showcasing their broad focus within the cannabinoid therapeutic space. Moreover, the company maintains a subsidiary interest in marketing hemp seed oil-based products, further extending its presence within the cannabinoid industry.

SciSparc, THC, Trial, Tourette, Pharmaceuticals, Cannabinoid, FDA